Tiger Brokers

HK StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

HANXBIO-B

19.160
+0.3601.91%
Volume:474.00K
Turnover:8.98M
Market Cap:2.61B
PE:-20.87
High:19.390
Open:19.390
Low:18.250
Close:18.800
52wk High:29.480
52wk Low:13.480
Shares:136.22M
HK Float Shares:136.22M
Volume Ratio:3.61
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.918
ROE:-43.61%
ROA:-13.64%
PB:13.87
PE(LYR):-20.87
PS:1048.33

Loading ...

OverviewCompanyNewsFilings

Company Profile

Company Name:
HANXBIO-B
Exchange:
SEHK
Establishment Date:
2014
Employees:
55
Office Location:
Building A8, Phase II,Bio-Innovation Park,No. 1 Jiufeng 1st Road,E. Lk New Tech Dev Zn,Wuhan,Hubei Province,China
Website:
http://www.hanxbio.com/
Zip Code:
- -
Phone:
86 27 6552 4978
Fax:
- -
Introduction:
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.

Directors

Name
Position
FAMING ZHANG
Chairman of the Board,Executive Director,Chairman of the Nomination Committee
LI Qi Xiang
Executive Director,Member of the Remuneration and Assessment Committee
LIU Min
Executive Director,COO
XIAO Jie Yu
Executive Director,Member of the Nomination Committee
ZHANG Qiong Guang
Independent Director,Member of the Nomination Committee,Audit Committee Member
BI Hong Gang
Independent Director,Member of the Remuneration and Assessment Committee,Member of the Nomination Committee
CHEN Qi Feng
Independent Director,Member of the Nomination Committee,Audit Committee Chairman
WANG Shi Xiong
Independent Director,Chairman of the Remuneration and Assessment Committee,Audit Committee Member
LI Jian
Director
KE Hang
Supervisor,Supervisory
SUN Peng
Supervisory
CHEN Chen
Employee Supervisor

Shareholders

Name
Position
LI Qi Xiang
CEO,General Manager,Chief Science Officer
LIU Min
Vice General Manager
ZHANG Lei
Vice General Manager,Other Senior Executives
XIAO Jie Yu
CFO,Board Secretary
LI Jian Wei
Corporate Secretary
Weimin Tang
Chief Business Officer